1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014

Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) 24
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials 29
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
F. Hoffmann-La Roche Ltd. 32
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 32
Eli Lilly and Company 33
Clinical Trial Overview of Eli Lilly and Company 33
Bristol-Myers Squibb Company 34
Clinical Trial Overview of Bristol-Myers Squibb Company 34
AstraZeneca PLC 35
Clinical Trial Overview of AstraZeneca PLC 35
Eisai Co., Ltd. 36
Clinical Trial Overview of Eisai Co., Ltd. 36
Boehringer Ingelheim GmbH 37
Clinical Trial Overview of Boehringer Ingelheim GmbH 37
Biotest AG 38
Clinical Trial Overview of Biotest AG 38
Astellas Pharma Inc. 39
Clinical Trial Overview of Astellas Pharma Inc. 39
Altor BioScience Corporation 40
Clinical Trial Overview of Altor BioScience Corporation 40
Clinical Trial Overview of Top Institutes / Government 41
National Cancer Institute 41
Clinical Trial Overview of National Cancer Institute 41
The University of Chicago 42
Clinical Trial Overview of The University of Chicago 42
European Organization for Research and Treatment of Cancer 43
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 43
Icahn School of Medicine at Mount Sinai 44
Clinical Trial Overview of Icahn School of Medicine at Mount Sinai 44
Memorial Sloan Kettering Cancer Center 45
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 45
Barts and The London NHS Trust 46
Clinical Trial Overview of Barts and The London NHS Trust 46
The Wales Cancer Trials Unit 47
Clinical Trial Overview of The Wales Cancer Trials Unit 47
Northern California Cancer Center 48
Clinical Trial Overview of Northern California Cancer Center 48
The University of Texas M. D. Anderson Cancer Center 49
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 49
Five Key Clinical Profiles 50
Appendix 118
Abbreviations 118
Definitions 118
Research Methodology 119
Secondary Research 119
About GlobalData 120
Contact Us 120
Disclaimer 120
Source 121

List of Tables
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 15
Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 32
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 33
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 34
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 35
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2014* 36
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Boehringer Ingelheim GmbH, 2014* 37
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Biotest AG, 2014* 38
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014* 39
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Altor BioScience Corporation, 2014* 40
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 41
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014* 42
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 43
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Icahn School of Medicine at Mount Sinai, 2014* 44
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 45
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Barts and The London NHS Trust, 2014* 46
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The Wales Cancer Trials Unit, 2014* 47
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Northern California Cancer Center, 2014* 48
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 49

List of Figures
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 119

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.